Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.

MLA

Blauvelt, Andrew, et al. “Safety of Guselkumab in Patients with Psoriasis with a History of Malignancy: 5-Year Results from the VOYAGE 1 and VOYAGE 2 Trials.” British Journal of Dermatology, vol. 189, no. 1, July 2023, pp. 132–34. EBSCOhost, https://doi.org/10.1093/bjd/ljad081.

APA

Blauvelt, A., Thaçi, D., Papp, K. A., Ho, V., Ghoreschi, K., Kim, B. S., Miller, M., Shen, Y.-K., You, Y., Chan, D., Yu, J., Yang, Y.-W., Lebwohl, M. G., Gottlieb, A. B., Crowley, J., & Foley, P. (2023). Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials. British Journal of Dermatology, 189(1), 132–134. https://doi.org/10.1093/bjd/ljad081

Chicago

Blauvelt, Andrew, Diamant Thaçi, Kim A Papp, Vincent Ho, Kamran Ghoreschi, Byung Soo Kim, Megan Miller, et al. 2023. “Safety of Guselkumab in Patients with Psoriasis with a History of Malignancy: 5-Year Results from the VOYAGE 1 and VOYAGE 2 Trials.” British Journal of Dermatology 189 (1): 132–34. doi:10.1093/bjd/ljad081.